A Study Investigating the Pharmacokinetic Properties of a Single Dose of IcoSema Compared With Insulin Icodec and Semaglutide Given Separately in Chinese Participants With Type 2 Diabetes
Latest Information Update: 23 Mar 2025
At a glance
- Drugs Insulin icodec (Primary) ; Insulin-icodec/semaglutide (Primary) ; Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
Most Recent Events
- 21 Aug 2023 Status changed from recruiting to completed.
- 05 Jul 2022 New trial record